Or­ca Bio looks to in­crease its cell ther­a­py man­u­fac­tur­ing ca­pac­i­ty with a new fa­cil­i­ty in Sacra­men­to

While Or­ca Bio has net­ted some ma­jor mile­stones, such as a $192 mil­lion Se­ries D and a re­gen­er­a­tive med­i­cine ad­vanced ther­a­py (RMAT) des­ig­na­tion from the FDA, the com­pa­ny is look­ing to step up things on the man­u­fac­tur­ing side of the busi­ness.

Or­ca Bio will ex­pand its man­u­fac­tur­ing ca­pa­bil­i­ties by con­struct­ing a new 100,000-square-foot com­mer­cial fa­cil­i­ty in Sacra­men­to, CA.

In an in­ter­view with End­points News, Or­ca Bio COO Jeroen Bekaert said the biotech is now evolv­ing in­to a late-stage cell ther­a­py com­pa­ny and is start­ing its Phase III with the Or­ca-T prod­uct, which has in­creased their need for man­u­fac­tur­ing space.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER